Annexon Biosciences Stock

annexonbio.comHealthcareFounded: 2011Funding to Date: $154MM

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain.

Register for Details

For more details on financing and valuation for Annexon Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Annexon Biosciences.

Register Today

Team

Management Team

Jennifer Lew
Chief Financial Officer
Ted Yednock Ph.D
Chief Scientific Officer & Executive Vice President
Sanjay Keswani
Chief Medical Officer
Douglas Love JD
Chief Executive Officer, President & Board Member
Lesley Stolz Ph.D
Chief Business Officer

Board Members

Carol Gallagher
New Enterprise Associates
Giovanni Ferrara
Novartis Venture Fund
Stacie Weninger Ph.D
Emmett Cunningham Ph.D
Blackstone Life Sciences
Douglas Love JD
Frank Torti MD
New Enterprise Associates
Ricky Sun Ph.D
Bain Capital
William Young
Blackstone Life Sciences
Campbell Murray MD
Novartis Venture Fund
Muneer Satter JD
Satter Foundation
Thomas Wiggans

Other companies like Annexon Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

Annexon Biosciences, a South San Francisco, CA-based biopharmaceutical company developing classical complement pathway inhibitors to treat neurodegenerative disorders, closed $44m Series B financing round. The round was led by new investor New Enterprise Associates (NEA), with participation from Correlation Ventures and existing investors Novartis Venture Fund, Clarus, and Satter Investment Management, LLC. In conjunction with …